Pfizer's updated COVID-19 vaccine approved, Health Canada says
Pfizer-BioNTech's updated vaccine to protect against a recently circulating variant of COVID-19 is authorized, Health Canada said on Tuesday.
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 variant adapted COMIRNATY® COVID-19 vaccine for ages 6 months and older. The updated COMIRNATY® vaccine targets the Omicron KP.
Health Canada approves Pfizer-BioNTech's updated COVID-19 vaccine
BioNTech's updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against the most recently circulating variants of the virus.
Moderna's updated COVID-19 vaccine is coming to Alberta, but Novavax shots are not
With the approval of Moderna's updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans will opt to roll up their sleeves to get one.
On the hunt for Novavax: Why people are seeking out the 'traditional' COVID vaccine
Although Pfizer's and Moderna’s COVID-19 vaccines have been stealing the spotlight for years, some people are actively seeking out the lesser-known Novavax for their updated booster this fall. Multiple people have been claiming on social media that Novavax comes with fewer side effects or none at all — “not even a sore arm,
Zacks.com on MSN7h
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...
Pfizer Unusual Options Activity
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...
Pfizer Inc. stock outperforms competitors despite losses on the day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Pfizer: Undervalued Healthcare Leader Poised For Further Recovery
Pfizer's stock underperformed its healthcare peers since PFE topped out in late July 2024. Click here to find out why I ...
Is Pfizer's 5.7% Dividend Yield Worth the Risk?
Pharmaceutical giant Pfizer ( PFE 2.73%) stands out in this context. The company currently offers a mouthwatering 5.7% ...
Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi
Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...
Jefferies Sticks to Its Buy Rating for Pfizer (PFE)
Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $35.00. The ...
Global News7h
Pfizer’s updated COVID-19 vaccine approved by Health Canada
Health Canada has approved Pfizer-BioNTech’s updated COVID-19 vaccine that protects against one of the most recently ...
Pfizer Inc. (PFE): Why Are Street Analysts Bullish On This Wide Moat Stock Now?
We recently compiled a list of the 8 Best Wide Moat Stocks to Buy According to Analysts. In this article, we are going to ...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...